|
1
|
Rosen EM, Fan S, Pestell RG and Goldberg
ID: BRCA1 gene in breast cancer. J Cell Physiol. 196:19–41. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roy R, Chun J and Powell SN: BRCA1 and
BRCA2: Different roles in a common pathway of genome protection.
Nat Rev Cancer. 12:68–78. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Joo WS, Jeffrey PD, Cantor SB, Finnin MS,
Livingston DM and Pavletich NP: Structure of the 53BP1 BRCT region
bound to p53 and its comparison to the Brca1 BRCT structure. Genes
Dev. 16:583–593. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mullan PB, Quinn JE and Harkin DP: The
role of BRCA1 in transcriptional regulation and cell cycle control.
Oncogene. 25:5854–5863. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Streff H, Profato J, Ye Y, Nebgen D,
Peterson SK, Singletary C, Arun BK and Litton JK: Cancer incidence
in first- and second-degree relatives of BRCA1 and BRCA2 mutation
carriers. Oncologist. 21:869–874. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Linger RJ and Kruk PA: BRCA1 16 years
later: Risk-associated BRCA1 mutations and their functional
implications. FEBS J. 277:3086–3096. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilson CA, Ramos L, Villaseñor MR, Anders
KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D,
et al: Localization of human BRCA1 and its loss in high-grade,
non-inherited breast carcinomas. Nat Genet. 21:236–240. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sun C, Li N, Yang Z, Zhou B, He Y, Weng D,
Fang Y, Wu P, Chen P, Yang X, et al: miR-9 regulation of BRCA1 and
ovarian cancer sensitivity to cisplatin and PARP inhibition. J Natl
Cancer Inst. 105:1750–1758. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pennington KP, Walsh T, Harrell MI, Lee
MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord
AS, et al: Germline and somatic mutations in homologous
recombination genes predict platinum response and survival in
ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer
Res. 20:764–775. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Esteller M, Silva JM, Dominguez G, Bonilla
F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky
EA, et al: Promoter hypermethylation and BRCA1 inactivation in
sporadic breast and ovarian tumors. J Natl Cancer Inst. 92:564–569.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moskwa P, Buffa FM, Pan Y, Panchakshari R,
Gottipati P, Muschel RJ, Beech J, Kulshrestha R, Abdelmohsen K,
Weinstock DM, et al: miR-182-mediated downregulation of BRCA1
impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell.
41:210–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Z, Liu J, Segura MF, Shao C, Lee P,
Gong Y, Hernando E and Wei JJ: MiR-182 overexpression in
tumourigenesis of high-grade serous ovarian carcinoma. J Pathol.
228:204–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alexandrov LB, Nik-Zainal S, Siu HC, Leung
SY and Stratton MR: A mutational signature in gastric cancer
suggests therapeutic strategies. Nat Commun. 6:86832015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang ZZ, Liu YJ, Yin XL, Zhan P, Gu Y and
Ni XZ: Loss of BRCA1 expression leads to worse survival in patients
with gastric carcinoma. World J Gastroenterol. 19:1968–1974. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen W, Wang J, Li X, Li J, Zhou L, Qiu T,
Zhang M and Liu P: Prognostic significance of BRCA1 expression in
gastric cancer. Med Oncol. 30:4232013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kim JW, Cho HJ, Kim M, Lee KH, Kim MA, Han
SW, Oh DY, Lee HJ, Im SA, Kim TY, et al: Differing effects of
adjuvant chemotherapy according to BRCA1 nuclear expression in
gastric cancer. Cancer Chemother Pharmacol. 71:1435–1443. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen XR, Zhang WZ, Lin XQ and Wang JW:
Genetic instability of BRCA1 gene at locus D17S855 is related to
clinicopathological behaviors of gastric cancer from Chinese
population. World J Gastroenterol. 12:4246–4249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang K, Xu L, Pan L, Xu K and Li G: The
functional BRCA1 rs799917 genetic polymorphism is associated with
gastric cancer risk in a Chinese Han population. Tumour Biol.
36:393–397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH,
Lee JH, Kim HN, Shin MH, Kweon SS, Lee JH, et al: BRCA1 and XRCC1
polymorphisms associated with survival in advanced gastric cancer
treated with taxane and cisplatin. Cancer Sci. 101:1247–1254. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang D and Lippard SJ: Cellular processing
of platinum anticancer drugs. Nat Rev Drug Discov. 4:307–320. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Borst P, Rottenberg S and Jonkers J: How
do real tumors become resistant to cisplatin? Cell Cycle.
7:1353–1359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zimmermann T, Zeizinger M and Burda JV:
Cisplatin interaction with cysteine and methionine, a theoretical
DFT study. J Inorg Biochem. 99:2184–2196. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Circu ML and Aw TY: Reactive oxygen
species, cellular redox systems, and apoptosis. Free Radic Biol
Med. 48:749–762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martinez-Balibrea E, Martínez-Cardús A,
Ginés A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Bugés
C, Bystrup S, Esteller M and Abad A: Tumor-related molecular
mechanisms of oxaliplatin resistance. Mol Cancer Ther.
14:1767–1776. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ajani JA: Evolving chemotherapy for
advanced gastric cancer. Oncologist. 10 Suppl 3:S49–S58. 2005.
View Article : Google Scholar
|
|
27
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carcas LP: Gastric cancer review. J
Carcinog. 13:142014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jung KW, Won YJ, Oh CM, Kong HJ, Cho H,
Lee JK, Lee DH and Lee KH: Prediction of cancer incidence and
mortality in Korea, 2016. Cancer Res Treat. 48:451–457. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mueller CR and Roskelley CD: Regulation of
BRCA1 expression and its relationship to sporadic breast cancer.
Breast Cancer Res. 5:45–52. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
McMillen BD, Aponte MM, Liu Z, Helenowski
IB, Scholtens DM, Buttin BM and Wei JJ: Expression analysis of
MIR182 and its associated target genes in advanced ovarian
carcinoma. Mod Pathol. 25:1644–1653. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park JG, Frucht H, LaRocca RV, Bliss DP
Jr, Kurita Y, Chen TR, Henslee JG, Trepel JB, Jensen RT, Johnson
BE, et al: Characteristics of cell lines established from human
gastric carcinoma. Cancer Res. 50:2773–2780. 1990.PubMed/NCBI
|
|
33
|
Park JG, Yang HK, Kim WH, Chung JK, Kang
MS, Lee JH, Oh JH, Park HS, Yeo KS, Kang SH, et al: Establishment
and characterization of human gastric carcinoma cell lines. Int J
Cancer. 70:443–449. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Swisher EM, Sakai W, Karlan BY, Wurz K,
Urban N and Taniguchi T: Secondary BRCA1 mutations in BRCA1-mutated
ovarian carcinomas with platinum resistance. Cancer Res.
68:2581–2586. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fink D, Nebel S, Aebi S, Zheng H, Cenni B,
Nehmé A, Christen RD and Howell SB: The role of DNA mismatch repair
in platinum drug resistance. Cancer Res. 56:4881–4886.
1996.PubMed/NCBI
|
|
36
|
Zdraveski ZZ, Mello JA, Farinelli CK,
Essigmann JM and Marinus MG: MutS preferentially recognizes
cisplatin-over oxaliplatin-modified DNA. J Biol Chem.
277:1255–1260. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nehmé A, Baskaran R, Aebi S, Fink D, Nebel
S, Cenni B, Wang JY, Howell SB and Christen RD: Differential
induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA
mismatch repair-proficient and -deficient cells exposed to
cisplatin. Cancer Res. 57:3253–3257. 1997.PubMed/NCBI
|
|
38
|
Nehmé A, Baskaran R, Nebel S, Fink D,
Howell SB, Wang JY and Christen RD: Induction of JNK and c-Abl
signalling by cisplatin and oxaliplatin in mismatch
repair-proficient and -deficient cells. Br J Cancer. 79:1104–1110.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vaisman A, Varchenko M, Umar A, Kunkel TA,
Risinger JI, Barrett JC, Hamilton TC and Chaney SG: The role of
hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin
resistance: Correlation with replicative bypass of platinum-DNA
adducts. Cancer Res. 58:3579–3585. 1998.PubMed/NCBI
|
|
40
|
Martin LP, Hamilton TC and Schilder RJ:
Platinum resistance: The role of DNA repair pathways. Clin Cancer
Res. 14:1291–1295. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Strathdee G, MacKean MJ, Illand M and
Brown R: A role for methylation of the hMLH1 promoter in loss of
hMLH1 expression and drug resistance in ovarian cancer. Oncogene.
18:2335–2341. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yamamoto H, Perez-Piteira J, Yoshida T,
Terada M, Itoh F, Imai K and Perucho M: Gastric cancers of the
microsatellite mutator phenotype display characteristic genetic and
clinical features. Gastroenterology. 116:1348–1357. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wu MS, Lee CW, Shun CT, Wang HP, Lee WJ,
Chang MC, Sheu JC and Lin JT: Distinct clinicopathologic and
genetic profiles in sporadic gastric cancer with different mutator
phenotypes. Genes Chromosomes Cancer. 27:403–411. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bacani J, Zwingerman R, Di Nicola N,
Spencer S, Wegrynowski T, Mitchell K, Hay K, Redston M, Holowaty E,
Huntsman D, et al: Tumor microsatellite instability in early onset
gastric cancer. J Mol Diagn. 7:465–477. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Leung SY, Yuen ST, Chung LP, Chu KM, Chan
AS and Ho JC: hMLH1 promoter methylation and lack of hMLH1
expression in sporadic gastric carcinomas with high-frequency
microsatellite instability. Cancer Res. 59:159–164. 1999.PubMed/NCBI
|
|
46
|
Pinto M, Oliveira C, Machado JC, Cirnes L,
Tavares J, Carneiro F, Hamelin R, Hofstra R, Seruca R and
Sobrinho-Simões M: MSI-L gastric carcinomas share the hMLH1
methylation status of MSI-H carcinomas but not their
clinicopathological profile. Lab Invest. 80:1915–1923. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fleisher AS, Esteller M, Wang S, Tamura G,
Suzuki H, Yin J, Zou TT, Abraham JM, Kong D, Smolinski KN, et al:
Hypermethylation of the hMLH1 gene promoter in human gastric
cancers with microsatellite instability. Cancer Res. 59:1090–1095.
1999.PubMed/NCBI
|
|
48
|
Scartozzi M, Galizia E, Freddari F,
Berardi R, Cellerino R and Cascinu S: Molecular biology of sporadic
gastric cancer: Prognostic indicators and novel therapeutic
approaches. Cancer Treat Rev. 30:451–459. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Eshleman JR and Markowitz SD: Mismatch
repair defects in human carcinogenesis. Hum Mol Genet. 5:1489–1494.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang Y, Cortez D, Yazdi P, Neff N, Elledge
SJ and Qin J: BASC, a super complex of BRCA1-associated proteins
involved in the recognition and repair of aberrant DNA structures.
Genes Dev. 14:927–939. 2000.PubMed/NCBI
|
|
51
|
Caldas C, Carneiro F, Lynch HT, Yokota J,
Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski
JA, et al: Familial gastric cancer: Overview and guidelines for
management. J Med Genet. 36:873–880. 1999.PubMed/NCBI
|
|
52
|
Wang Q, Zhang H, Guerrette S, Chen J,
Mazurek A, Wilson T, Slupianek A, Skorski T, Fishel R and Greene
MI: Adenosine nucleotide modulates the physical interaction between
hMSH2 and BRCA1. Oncogene. 20:4640–4649. 2001. View Article : Google Scholar : PubMed/NCBI
|
